Clinical Trials Browser

Withdrawn × Vorinostat × Dermatologic × Clear all

NCT03022565 2020-02-06

Vorinostat in Patients With Class 2 High Risk Uveal Melanoma

Phase EARLY_PHASE1 Withdrawn

Uveal Melanoma

NCT01386398 2015-01-21

Vorinostat With or Without Bortezomib in Treating Patients With Refractory or Recurrent Stage IIB, Stage III, or Stage IV Cutaneous T-Cell Lymphoma

Phase 3 Withdrawn

DermatologicLymphoid

Lymphoma, Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous